

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1.-106. (Canceled)

107. (Currently amended) A method for modifying the fucosylation pattern of a recombinant glycopeptide comprising an acceptor, said method comprising:

contacting a full-length recombinant glycopeptide with a reaction mixture that comprises a fucose donor moiety and a fucosyltransferase under appropriate conditions *in vitro* to transfer fucose from the fucose donor moiety to the acceptor moiety, such that the glycopeptide has a substantially uniform fucosylation pattern;

wherein said acceptor moiety is Gal β 1,4GlcNAc-OR or NeuAc α 2,3Gal β 1,4GlcNAc-OR, wherein R is an amino acid, a saccharide, an oligosaccharide or an aglycon group having at least one carbon atom and is linked to or is part of a glycopeptide, and

wherein said ~~eukaryotic~~ fucosyltransferase is an isolated, recombinantly produced human FucT-VI or human FucT-VII fucosyltransferase wherein said ~~eukaryotic~~ fucosyltransferase lacks a membrane anchoring domain, and wherein said fucosyltransferase provides at least 2-fold greater fucosylation of said glycopeptide than is achieved under identical conditions using recombinant, isolated FucT-V.

108. (Currently amended) The method of claim 107, 115 or 117, wherein the concentration of said recombinant ~~eukaryotic~~ human FucT-VI or FucT-VII fucosyltransferase is at least 1 Unit/ml.

109. (Currently amended) The method of claim 107, 115 or 117, wherein the fucosyltransferase is human FucT-VI.

110. (Currently amended) The method of claim 107, 115 or 117, wherein the fucosyltransferase is human FucT-VII.

111. (Previously presented) The method of claim 107, 115 or 117, wherein said full-length recombinant glycopeptide is a clotting factor.

112. (Previously presented) The method of claim 111, wherein said clotting factor is selected from the group consisting of Factor VIII and Factor IX.

113-114. (Canceled)

115. (Currently amended) The method of claim 107, wherein said isolated, recombinantly produced human fucosyltransferase provides at least 4-fold greater fucosylation of said glycopeptide than is achieved under identical conditions using said isolated FucT-V.

116. (Canceled)

117. (Currently amended) The method of claim 115, wherein said isolated, recombinantly produced human fucosyltransferase provides at least 8-fold greater fucosylation of said glycopeptide than is achieved under identical conditions using said isolated FucT-V.

118. (Canceled)

119. (Previously presented) The method of claim 107, 115 or 117, wherein said recombinant glycoprotein is present at a concentration of at least 2 mg/ml.

120. (Currently amended) The method of claim 107, 115 or 117, wherein the concentration of said recombinant ~~eukaryotic~~ human FucT-VI or FucT-VII fucosyltransferase is 50mU or less of said fucosyltransferase per mg of glycopeptide.